Company profile: C2i Genomics
1.1 - Company Overview
Company description
- Provider of cloud-based cancer diagnostic services for pharmaceutical and diagnostic organizations, offering the C2-Intelligence Platform that leverages whole-genome sequencing and AI to detect minimal residual disease, low-input liquid biopsy, and services for MRD-guided adjuvant treatment, organ preservation decisions, treatment response monitoring, and early recurrence detection.
Products and services
- C2-Intelligence Platform: Cloud-based platform leveraging whole-genome sequencing and AI to detect minimal residual disease in cancer patients, delivering insights for treatment decisions
- Low-input Liquid Biopsy: A low-input blood test requiring only 2-3ml of blood to detect cancer-specific DNA signatures for monitoring tumor burden and treatment response
- Treatment Response Monitoring: An MRD-based service to monitor residual disease during therapy, assessing treatment effectiveness and guiding adjustments to improve patient management
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to C2i Genomics
IBA Lifesciences
HQ: Germany
Website
- Description: Provider of life science technologies including the Strep-tag system for high-purity, high-yield recombinant protein purification and analysis; Strep-Tactin XT for strong, reversible binding to Twin-Strep-tag peptides; MagStrep Strep-Tactin XT beads and Strep-Tactin XT 4Flow resins for efficient purification; the MEXi mammalian cell production system; and StrepMAB-Immo for SPR analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IBA Lifesciences company profile →
Day Zero Diagnostics
HQ: United States
Website
- Description: Provider of whole-genome sequencing–based tools and services for clinical pathogen detection, antimicrobial resistance profiling, and outbreak management, including Blood2Bac to enrich bacterial DNA directly from blood; Keynome ID for species identification; Keynome gAST for resistance profiling; MicrohmDB to support machine learning; and epiXact for pathogen relatedness insights for infection control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Day Zero Diagnostics company profile →
Seer
HQ: United States
Website
- Description: Provider of proteomics tools and solutions, including the Proteograph Product Suite (integrated workflow with instruments, consumables, and software for deep, large-scale proteome analysis); Proteograph Analysis Suite for LC-MS data processing, analysis, and visualization; SP100 Automation Instrument; Proteograph Assay Kit; and Seer Technology Access Center services for proteomics research support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seer company profile →
Switchback Systems
HQ: United States
Website
- Description: Provider of offerings aimed at democratizing DNA synthesis as an early-stage startup.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Switchback Systems company profile →
Verve Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage genetic medicines for cardiovascular disease, including gene editing therapies VERVE-101 targeting PCSK9 to lower LDL-C in heterozygous familial hypercholesterolemia and ASCVD, and VERVE-201 targeting ANGPTL3 for homozygous and refractory hypercholesterolemia, enabled by a proprietary GalNAc-LNP liver delivery system, with medicines evaluated in clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verve Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for C2i Genomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to C2i Genomics
2.2 - Growth funds investing in similar companies to C2i Genomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for C2i Genomics
4.2 - Public trading comparable groups for C2i Genomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →